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Background: Aripiprazole is an atypical antipsychotic drug that is characterized by
partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to
be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic
disorders. This study compared brain activation characteristics produced by aripiprazole
with that of haloperidol, a typical D2 receptor antagonist, during a task targeting
executive functioning.
Methods: Healthy participants received an acute oral dose of haloperidol, aripiprazole
or placebo before performing an executive functioning task while blood-oxygen-level-
dependent (BOLD) functional magnetic resonance imaging (fMRI) was carried out.
Results: There was a tendency towards reduced performance in the aripiprazole
group compared to the two other groups. The image analysis yielded a strong task-
related BOLD-fMRI response within each group. An uncorrected between-group analysis
showed that aripiprazole challenge resulted in stronger activation in the frontal and
temporal gyri and the putamen compared with haloperidol challenge, but after correcting
for multiple testing there was no significant group difference.
Conclusion: No significant group differences between aripiprazole and haloperidol in
frontal cortical activation were obtained when corrected for multiple comparisons. This
study is registered in ClinicalTrials.gov (identifier: 2009-016222-14).1
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Introduction
Cognitive impairment is recognized as an important characteristic of psychosis, being present
in schizophrenia patients and in high-risk individuals(Schaefer et al., 2013; Bora et al., 2014;
Fatouros-Bergman et al., 2014). Cognitive deficits are good predictors of functional outcome
in schizophrenia, and therefore an important treatment target (Green, 1996). There has been
1https://clinicaltrials.gov/
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great effort to determine the effects of different types of
antipsychotics on cognitive dysfunction, which together with
negative symptoms, is far more difficult to treat than positive
symptoms. The effect of antipsychotics on cognitive impairment
is weak to moderate (Cuesta et al., 2001; Davidson et al.,
2009). However, there is a large variation in the results
on important cognitive domains such as executive function,
attention and memory (Désaméricq et al., 2014); this may reflect
different pharmacodynamic profiles. In general, it is suggested
that atypical antipsychotics with relatively low dopamine and
high serotonin receptor affinity improve cognitive functioning
compared to typical antipsychotics with strong dopamine
antagonism (Mishara and Goldberg, 2004; Désaméricq et al.,
2014), and this has been associated with increased frontal cortical
activation (Liemburg et al., 2012).
The antipsychotic effect of antipsychotic drugs is suggested
to be directly related to dopamine D2 receptor affinity (Seeman
and Lee, 1975). The Dopamine hypothesis of schizophrenia
postulates that psychosis is due to dopamine system disturbances
influenced by multiple risk factors including genetic and
social environmental factors, in interaction with other
neurotransmitter system disturbances (Howes and Kapur,
2009). The disturbances manifest as hyperactivity in the striatum,
mainly associated with increased presynaptic dopamine synthesis
capacity (Howes et al., 2012), and hypoactivity in the frontal
cortex that is thought to be related to the striatal dopaminergic
dysfunction (Meyer-Lindenberg et al., 2002); the latter issue
being somewhat inconsistent (Manoach, 2003).
Typical (first generation) antipsychotic drugs exhibit mainly
high affinity dopamine D2 receptor antagonism, whereas atypical
(second generation) antipsychotic drugs target several other
receptor types in addition. Aripiprazole is a relatively new drug
that by some patients is tolerated better than other atypical
antipsychotics because it gives less metabolic side effects (weight
gain, dyslipidemia and diabetes mellitus; Citrome et al., 2014).
In addition to having a relatively strong affinity for serotonin
(5-hydroxytryptamine) 5-HT2A and 5-HT1A receptors, it is also
a partial agonist at the dopamine D2 receptor. It is thought to
display antagonistic properties in a dopamine-rich environment,
and agonistic properties in a dopamine-deficient environment
(Burris et al., 2002; Shapiro et al., 2003). Hence, aripiprazole
has held promise for a more complete treatment of psychotic
disorders, including schizophrenia (Tamminga, 2002). However,
even though it effectively decreases positive symptoms, its
efficacy in treating cognitive dysfunction and negative symptoms
is less clear. The majority of studies report a variable degree
of improvement (Schlagenhauf et al., 2010; Suzuki et al., 2011;
Wang et al., 2013; Maat et al., 2014; Yeh et al., 2014), but
cognitive impairment has also been found (Yasui-Furukori et al.,
2012). To gain a better understanding of how antipsychotics
affect cognitive functions it is crucial to disentangle the effects
of illness and medication. One way to gain new insight is
by studying effects of antipsychotics on cognition in healthy
individuals.
Yet, only a few reports describe effects of antipsychotic
drugs on cognition in healthy subjects. Decreased cognitive
performance related to attention, response time and information
processing have been reported for subjects given up to five
doses of the typical antipsychotic drug haloperidol (Ramaekers
et al., 1999; Saeedi et al., 2006; Vernaleken et al., 2006).
Studies of atypical antipsychotics have shown impairments
(Ramaekers et al., 1999; Morrens et al., 2007; amisulpride
and olanzapine, respectively), no effect (Chung et al., 2012;
aripiprazole) or improvement (Chung et al., 2012; amisulpride)
on cognitive functioning. One functional magnetic resonance
imaging (fMRI) study found no difference in neural activation
when comparing sulpiride and placebo (Dodds et al., 2009).
Aripiprazole have been examined in three neuroimaging studies
this far. Using positron emission tomography (PET; Kim
et al., 2013) found reduced frontal metabolism associated with
extended response times. Another study showed increased
striatal and decreased frontal regional cerebral blood flow
(rCBF), presumably reflecting increased presynaptic dopamine
synthesis and release in the striatum (Handley et al., 2013).
Goozee et al. (2015) reported differences in neural activation
between aripiprazole and haloperidol during a working memory
task. More knowledge is needed about the effects of antipsychotic
medication on cognition in general, and specifically about
the functional brain activations related to antipsychotics with
different pharmacodynamic profiles. The current study aimed
to identify differences in brain activity related to cognition
in healthy individuals given either aripiprazole or haloperidol.
By using the Tower of London (ToL) task, targeting executive
functioning (Sullivan et al., 2009), we directly compared
brain activations associated by the two drugs in an fMRI
experiment. We hypothesized that aripiprazole would yield




This study was approved by the Norwegian Regional Committees
for Medical and Health Research Ethics, The Norwegian
Medicines Agency and is registered in ClinicalTrials.gov
(identifier: 2009-016222-14). All participants had responded
to posted advertisement, gave written informed consent and
were financially compensated. Participants were included if
they passed somatic and psychiatric health screening, and had
not taken psychotropic medication the previous 2 years or
any drugs or medications the last 2 weeks. Three subjects
were excluded based on abnormal electrocardiograms, and
two based on structural brain abnormalities. The included
subjects were randomized into one of three groups and given
aripiprazole, haloperidol or placebo (eighteen individuals per
group).
Subjects were challenged with one single dose at one time 4.8
(Range 4.0–5.6) hours prior to the fMRI scan. They were given
either 10 or 15 mg of aripiprazole, 2 or 3 mg of haloperidol or
placebo, all delivered as two or three pills based on their body
weight (≤75 kg or >75 kg). Out of the first eight subjects that
were given a drug, three subjects were unsuitable for scanning
due to side effects. Therefore, the dose regime was subsequently
lowered to 5 or 10 mg of aripiprazole or 1 or 2 mg of haloperidol.
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Two datasets (one haloperidol, one aripiprazole) were
excluded from analysis due to excessive head movement in
the scanner (>3 mm), and one data set (aripiprazole) was lost
due to technical problems. In total, 48 datasets were subjected
to analysis. Table 1 displays demographic data and doses for
subjects included in the analysis.
Experimental Task
The ToL task is depicted in Figure 1 (Shallice, 1982). All
participants completed a training version of the experimental
task prior to the MRI scan. In the scanner, the subjects were
first presented with an information screen, and asked to confirm
that they understood the instructions before the task was
presented.
fMRI Data Acquisition
The task stimuli were presented through VisualSystem goggles
and responses collected by ResponseGrip (Nordic Imaging Lab,
Bergen, Norway). The E-Prime software (Psychology Software
Tools Inc., Pittsburgh, Pennsylvania, USA) was used to present
the task and to collect responses.
The MR examinations were performed on a 3T General
Electric Signa HDxt scanner (GE Healthcare, Milwaukee,
WI, USA). The blood-oxygen-level-dependent (BOLD) fMRI
protocol consisted of a T2∗-weighted echo-planar imaging (EPI)
sequence in the transverse plane. The parameters were: repetition
time (TR) = 2 s; echo time (TE) = 25 ms; flip angle (FA) = 78
degrees; matrix = 64; field-of-view (FOV) = 256 mm; slice
thickness = 3.5 mm; gap = 0.5 mm; slices = 36. One run of
292 volumes was collected for each individual and the three
initial volumes were discarded. Structural T1-weighted images
were collected with the following parameters: TR = 7.7 s;
TE = 3.0 s; FA = 12 degrees; matrix = 256; FOV = 256; slice
thickness = 1.2 mm; slices = 172. These were obtained on a
day prior to the fMRI and used in the functional image pre-
processing and for radiological screening to identify subjects with
structural brain abnormalities.
Behavior Analysis
The behavioral data were analyzed using Statistical Package
for the Social Sciences (SPSS, Version 21, SPSS Inc., Chicago,
Illinois, USA). T-tests were used to analyze response times, while
Wilcoxon signed rank tests andMann-Whitney U tests were used
to analyze accuracy and number of completed tasks. Spearman
coefficients were used to describe associations between doses,
beta values and behavioral data. Analyses of response times are
based on problems with correct answers.
TABLE 1 | Demographical data and doses.
n Age Sex (males) Doses (mg/kg)
Aripiprazole 14 25.9 (7.6) 7 0.11 (0.029)
Haloperidol 16 25.1 (7.1) 7 0.02 (0.007)
Placebo 18 23.5 (3.1) 8
Age and doses are given in means and standard deviations.
FIGURE 1 | Depiction of the experimental task. During a task block the
participants solved as many Tower of London problems as they could within
32 s. The object of the task was to mentally calculate how many moves (2, 3,
4, or 5) were needed to manipulate the balls on the lower pegboard to reach
the goal configuration depicted in the upper pegboard, moving only one ball at
a time. Answers were indicated by button presses of right and left thumbs and
index fingers. Control blocks were comprised of four tasks of 8 s duration
where subjects were asked to push the indicated button.
Image Analysis
Data pre-processing and analyses was performed using the
Statistical Parametric Mapping software 8 (SPM8)2 implemented
in Matlab 7.5 (Mathworks, Natick, Massachusetts, US).
Structural images were normalized to the Montreal Neurological
Institute (MNI) reference brain (Evans et al., 1992). Functional
images were aligned to the first volume of each time-series and
spatially normalized using the parameters from the structural
image normalization, resampled to 3 mm isotropic voxels, and
smoothed using an 8 mm full-width at half-maximum Gaussian
isotropic kernel and high-pass filtered using a 128 s cut-off
value.
The model consisted of a canonical hemodynamic response
function convolved with box-car functions for onsets for
experiment and control conditions, in addition to movement
parameters. Individual contrast images (ToL task > Control
task) were moved to second-level random-effects analyses. To
test for task effects t-tests (corrected for multiple comparisons
at peak level threshold pFamily-wise error (FWE) < 0.05 and cluster
size (k) > 20 voxels) were performed across all three groups
2http://www.fil.ion.ucl.ac.uk/spm/
Frontiers in Human Neuroscience | www.frontiersin.org 3 May 2015 | Volume 9 | Article 296
Bolstad et al. Antipsychotics and the human frontal cortex
and within each group. To test the hypothesis that haloperidol
dampens activation more than aripiprazole in the frontal cortex
during a ToL task, a voxel-wise small volume correction was
used in a region-of-interest (ROI) analysis, followed by a test
of whole-brain effects. Activations from the placebo group were
used to construct a mask for the analysis of group effects between
aripiprazole and haloperidol, ensuring that an area specifically
targeted by this task served as ROI. In order to construct the
mask, clusters in the frontal cortex obtained using correction
for multiple comparisons for the whole brain were used. Five
activation clusters were identified at peak level threshold pFWE
< 0.05, k > 20 for the contrast ToL task > control task,




Behavioral data are given in Table 2.
Analysis of group effects revealed that the aripiprazole group
completed fewer tasks than the haloperidol group (U = 64.50,
p = 0.048). Comparisons between the drug and placebo
groups were performed for completeness, and showed that the
aripiprazole group completed fewer tasks than the placebo group
(U = 67.00, p = 0.024). The numbers of completed tasks within
each level of difficulty (2, 3, 4, or 5 moves) are given in Table 2.
There were no significant differences in accuracy or response
times, and no behavioral effects between the haloperidol and
placebo groups. In the placebo group there was a positive
correlation between accuracy and average response time for
correct answers (ρ = 0.64, p = 0.004), and a negative correlation
between accuracy and number of completed tasks (ρ = 0.49,
p = 0.040), while there were no correlations within the drug
groups. To explore whether the drugs influenced performance,
doses (mg/kg) of aripiprazole and haloperidol were correlated
with the behavioral data. In the haloperidol group there was
a negative correlation between accuracy and dose (ρ = 0.56,
p = 0.025).
fMRI Findings
Whole brain analysis showed strong effects of task across all
groups with prominent activations in the occipital, parietal and
frontal cortex and in the thalamus (Figure 3). Within each
group there were similar patterns, although with some variation
(Table 3).
According to our hypothesis, an ROI analysis was performed
to test whether the activations in the frontal cortex, specifically
targeted by the task, differed between the aripiprazole and the
haloperidol groups. No significant differences were revealed with
the ROI analysis. Exploratory uncorrected whole-brain analyses
of aripiprazole > haloperidol and haloperidol > aripiprazole
were performed at threshold level p< 0.001, k ≥ 5 (Table 3).
Side Effects
Three subjects were unsuitable for scanning due to nausea,
dizziness (aripiprazole), or claustrophobia (haloperidol). Three
additional subjects reported nausea (aripiprazole). No subjects
reported any side effects at one day or one week after
participation in the study.
Discussion
The present study shows a strong effect of the ToL task within
the aripiprazole, haloperidol and placebo groups. The analyses
revealed no differences in frontal cortical activation between
the drug groups. Although aripiprazole and haloperidol have
different pharmacodynamic profiles, the results may reflect
similarities in their effect on brain activation. However, there
might have been group differences that were too small to be
detected in the present sample.
In the current study we used fMRI to directly compare
aripiprazole- with haloperidol-affected frontal cortical
activations. Few reports exist where neuroimaging has been
used to investigate effects of aripiprazole in healthy individuals.
One study showed a negative association between striatal D2
occupancy and frontal cortical metabolism after aripiprazole
(Kim et al., 2013). A recent fMRI study employing the n-back
FIGURE 2 | The mask used in the region-of-interest (ROI) analysis. The mask (displayed in red) was constructed of five activation clusters from the contrast of
Tower of London task > Control task from the placebo group.
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TABLE 2 | Behavioral data for the tower of London task.
Accuracy (%) Response times (ms) Number of completed tasks
2 moves 3 moves 4 moves 5 moves Total
Aripiprazole 77.8 (41.7–100.0) 7022 (1026) 6 (4–9) 6 (4–8) 6 (3–9) 4 (2–7) 22.5 (17–30)
Haloperidol 71.5 (52.4–100.0) 6217 (1295) 7 (5–10) 7 (3–10) 7 (3–10) 6 (2–8) 27.5 (16–36)
Placebo 80.1 (35.3–96.4) 6347 (1181) 7 (5–9) 8 (3–10) 7 (5–11) 6 (4–10) 26.0 (18–38)
Accuracy and number of completed tasks are given in medians and range. Response times are given in means and standard deviations.
task revealed decreased frontal activation after haloperidol, when
compared to placebo and aripiprazole (Goozee et al., 2015).
The current results cannot corroborate these findings as no
significant differences in frontal cortical response were identified
between the two drugs.
There are few previous studies investigating the effect of
antipsychotics on cognition in healthy volunteers (Veselinovic
et al., 2013). It has been shown that decreased performance
in working memory is associated with increasing striatal D2
receptor occupancy (Kim et al., 2013). Although employing a
different cognitive task, the current behavioral results are in line
with this finding, indicating that increased haloperidol dose was
associated with impaired task performance. Studies in patients
and healthy volunteers have shown that typical antipsychotics
are associated with larger cognitive impairments than atypical
antipsychotics (Chung et al., 2012; Désaméricq et al., 2014),
suggesting that haloperidol has a more detrimental effect on
cognitive function than aripiprazole. However, some reports
show a positive effect of haloperidol on cognitive performance
(Mishara and Goldberg, 2004). In line with this, the present
results show that the haloperidol group performed well and
there was a tendency for better average performance than
in the aripiprazole group. In the placebo group increased
accuracy was associated with increased response times and
decreased number of completed tasks. This relationship was
not found in the drug groups, maybe indicating a less efficient
performance. However, as the study was designed for fMRI, and
not optimized for detecting behavioral differences, these findings
are inconclusive.
The literature on dopaminergic manipulation in the frontal
cortex in healthy individuals is scarce, and thus the current
fMRI study of brain activation related to executive functioning
is exploratory. Differences in brain response between the two
drug groups were not identified, but it cannot be ruled out
that the absence of group differences in this study may be due
to lack of power. The drug effects on cognitive performance
and related brain activity are dependent on baseline dopamine
levels, and a between-subject design may not be optimal for
identifying differential effects of the drugs. However, with
repeated performance, the ToL task may be subject to training
effects thus making a within-subject design suboptimal. The ToL
task has been shown to yield different activation patterns that
correspond to different task components (Newman et al., 2009).
The components are not separated in the current version and it
is possible that this task is not sensitive enough to reveal group
differences. The advantage of the current ROI approach is that
the ROI is specifically relevant to the task used; however it is
possible that the approachmay bias the group result if the placebo
activation pattern cannot be generalized. Healthy subjects were
used in the current study, and translating the findings to patients
may be difficult as the present pharmacodynamic may differ
from that found in illness. Also, the effect of an acute dose may
differ from long-term treatment which is needed in patients,
and different neurophysiological mechanisms may be involved
FIGURE 3 | Activation maps for task activations across all subjects. Statistical parametric maps showing whole brain activations for the contrast Tower of
London task > Control task across groups. Colors refer to t-values as coded in the bar to the right. The activations are shown at threshold pFWE < 0.05, k > 20.
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TABLE 3 | fMRI activation clusters.
Size p Z x y z
PLACEBO
Middle frontal gyrus 380 <0.001 7.06 −30 5 58
Inferior occipital gyrus 2577 <0.001 6.71 36 −79 −8
Superior frontal gyrus 287 <0.001 6.16 30 −7 58
Cingulate gyrus 261 <0.001 6.16 −6 17 46
Midbrain 93 <0.001 5.94 −3 −22 −14
Cerebellum 373 <0.001 5.69 39 −64 −38
Thalamus 37 0.005 5.29 −24 −31 1
Insula 21 0.010 5.12 33 26 4
Cerebellum 80 0.011 5.10 −24 −37 −44
Middle frontal gyrus 22 0.014 5.03 39 38 40
ARIPIPRAZOLE
Precuneus 441 <0.001 6.71 18 −67 43
Precuneus 171 <0.001 5.95 −17 −70 43
Middle occipital gyrus 175 <0.001 5.76 −33 −82 13
Hippocampus 137 0.002 5.45 −24 −25 −5
Fusiform gyrus 30 0.002 5.41 48 −55 −20
Fusiform gyrus 40 0.003 5.37 −30 −61 −17
Medial frontal gyrus 39 0.008 5.18 0 20 49
Thalamus 43 0.010 5.15 15 −10 −2
HALOPERIDOL
Superior parietal lobule 954 <0.001 6.44 −27 −70 58
Angular gyrus 820 <0.001 5.96 30 −55 40
Superior frontal gyrus 78 <0.001 5.87 30 −4 58
Fusiform gyrus 59 <0.001 5.84 −30 53 −14
Middle frontal gyrus 43 <0.001 5.75 45 41 38
Orbitofrontal gyrus 45 0.001 5.61 27 53 −14
Middle frontal gyrus 23 0.001 5.60 −51 29 31
Superior frontal gyrus 148 0.003 5.38 −6 2 61
Inferior frontal gyrus 40 0.006 5.23 −45 11 28
ARIPIPRAZOLE > HALOPERIDOL
Middle temporal gyrus 10 <0.001 3.62 −66 −49 −5
Putamen 10 <0.001 3.44 −24 −16 −5
Middle frontal gyrus 5 0.001 3.28 36 47 −8
The upper parts of the table show peak voxels of significant clusters from the within-group contrasts of Tower of London task > Control task (pFWE < 0.05, k > 20). The
lower part of the table shows results from an uncorrected exploratory analysis of the comparison aripiprazole > haloperidol (punc. < 0.001, k > 5). The opposite contrast
yielded no significant clusters. Coordinates are given in Montreal Neurological Institute and Hospital (MNI) coordinate system.
(Grace et al., 1997). In contrast to studies conducted in patients,
an advantage of the current study was that secondary effects of
psychosis illness did not affect the results. However, potential
consequences of side effects cannot be ruled out, and may differ
between the two drugs. By using a crossover design future studies
may increase the sensitivity, and a more standardized dosing
protocol may also be beneficial. In addition, an event-related
paradigm would make it possible to examine the activations in
more detail.
Altered dopaminergic function in the striatum has been
associated with reduced activity in the frontal cortex in
schizophrenia patients and prodromal state individuals (Meyer-
Lindenberg et al., 2002; Howes et al., 2009). The results of
neuroimaging studies investigating the effects of antipsychotic
drugs on activation in the frontal cortex are inconsistent, but
most suggest that atypical antipsychotic drugs yield increased
activation compared to typicals (Liemburg et al., 2012). The
pharmacological profile of aripiprazole differs substantially from
other atypical profiles, but very few neuroimaging studies have
investigated aripiprazole. One fMRI study in schizophrenia
patients employing an n-back working memory paradigm found
improved activation in the frontal cortex after 4 weeks treatment
with aripiprazole after switching from a typical antipsychotic
(Schlagenhauf et al., 2010). In accordance with the Dopamine
hypothesis aripiprazole is expected to show a net stimulating
effect in the frontal cortex in patients with schizophrenia
as its partial agonism property is thought to be present
at low concentrations of endogenous dopamine (Howes and
Kapur, 2009). Thus, one tentative explanation for the lack of
difference in the present study may be that aripiprazole acts
more antagonistic in the frontal cortex in healthy individuals
than in schizophrenia patients, possibly resulting in activation
differences that are too small to detect with the current design.
Another interpretation relates to baseline dopamine levels. The
PFC response to increasing cognitive load is thought to follow
an inverted U-curve, and this is associated with dopamine
transmission (Mattay et al., 2003). In patients with schizophrenia
this curve is shifted leftwards (Egan et al., 2001). However, in
healthy individuals, aripiprazole may induce a rightward shift in
dopamine signaling leading to an impaired PFC response that
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is not differentiated from the effect of haloperidol. However,
this is speculative, and more research is needed to elucidate the
underlying mechanisms.
In conclusion, the current study revealed no significant
differences in activation in the frontal cortex between
aripiprazole challenge and haloperidol challenge in healthy
volunteers performing the ToL task. This may be attributed to
similarities between these two drugs’ effect on executive function
in healthy individuals. However, the absence of group difference
may also be caused by methodological limitations of the current
study, and the issue needs further exploration.
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